Nyxoah S.A.

NasdaqGM:NYXH Stock Report

Market Cap: US$313.9m

Nyxoah Valuation

Is NYXH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NYXH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NYXH?

Key metric: As NYXH barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NYXH. This is calculated by dividing NYXH's market cap by their current book value.
What is NYXH's PB Ratio?
PB Ratio2.9x
Book€104.71m
Market Cap€299.11m

Price to Book Ratio vs Peers

How does NYXH's PB Ratio compare to its peers?

The above table shows the PB ratio for NYXH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average15.2x
CVRX CVRx
5.8x17.1%US$360.3m
DCTH Delcath Systems
39.2x71.2%US$312.1m
OBIO Orchestra BioMed Holdings
4.6x5.4%US$219.3m
CLPT ClearPoint Neuro
11.1x10.2%US$326.5m
NYXH Nyxoah
2.9x14.2%US$299.1m

Price-To-Book vs Peers: NYXH is good value based on its Price-To-Book Ratio (2.9x) compared to the peer average (15.2x).

Price to Book Ratio vs Industry

How does NYXH's PB Ratio compare vs other companies in the US Medical Equipment Industry?

28 CompaniesPrice / BookEstimated GrowthMarket Cap
ADGM Adagio Medical Holdings
0.5xn/aUS$35.90m
CODX Co-Diagnostics
0.5x-8.3%US$32.25m
MHUA Meihua International Medical Technologies
0.1xn/aUS$18.77m
RVP Retractable Technologies
0.2xn/aUS$18.72m
NYXH 2.9xIndustry Avg. 2.6xNo. of Companies28PB0246810+
28 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NYXH is expensive based on its Price-To-Book Ratio (2.9x) compared to the US Medical Equipment industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is NYXH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NYXH PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NYXH's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NYXH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.20
US$15.01
+83.0%
28.1%US$19.22US$10.80n/a2
Nov ’25US$9.55
US$15.13
+58.5%
28.1%US$19.38US$10.89n/a2
Oct ’25US$9.23
US$15.18
+64.6%
35.3%US$20.54US$9.83n/a2
Sep ’25US$8.00
US$15.18
+89.8%
35.3%US$20.54US$9.83n/a2
Aug ’25US$8.31
US$14.49
+74.4%
40.3%US$20.33US$8.65n/a2
Jul ’25US$7.03
US$14.50
+106.2%
40.7%US$20.40US$8.59n/a2
Jun ’25US$9.41
US$16.82
+78.7%
35.5%US$22.78US$10.85n/a2
May ’25US$9.48
US$16.54
+74.5%
35.5%US$22.41US$10.67n/a2
Apr ’25US$12.26
US$17.88
+45.9%
27.3%US$22.76US$13.01n/a2
Mar ’25US$14.78
US$10.58
-28.4%
48.2%US$15.68US$5.48n/a2
Feb ’25US$10.97
US$10.58
-3.5%
48.2%US$15.68US$5.48n/a2
Jan ’25US$4.64
US$10.62
+128.8%
48.2%US$15.73US$5.50n/a2
Dec ’24US$4.94
US$11.36
+129.9%
34.3%US$15.25US$7.46n/a2
Nov ’24US$5.62
US$11.26
+100.4%
34.3%US$15.12US$7.40US$9.552
Oct ’24US$7.05
US$12.14
+72.2%
28.3%US$15.57US$8.71US$9.232
Sep ’24US$7.51
US$12.14
+61.8%
28.3%US$15.57US$8.71US$8.002
Aug ’24US$8.26
US$21.73
+163.0%
58.7%US$34.47US$8.98US$8.312

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Patterson Companies

US$1.8b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.62

7D

3.4%

1Y

-32.2%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$61.43

7D

4.4%

1Y

-17.1%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.35

7D

17.6%

1Y

102.0%